Kodai Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kodai Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$4M	Buy	+56,540	New	+$3.8M	0.16%	112

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kodai Capital Management's BMRN Position: Q1 2025 in Review

Kodai Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2025: 56,540 shares worth $4M. The stake represents 0.16% of the portfolio and ranks #112 among its holdings.

585 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Kodai Capital Management held 56,540 shares of BioMarin Pharmaceuticals worth $4M as of Q1 2025.
BioMarin Pharmaceuticals was a new Kodai Capital Management position in Q1 2025.
BioMarin Pharmaceuticals made up 0.16% of Kodai Capital Management's portfolio in Q1 2025, its #112 holding.
585 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Kodai Capital Management's 13F filing for Q1 2025, filed 15 May 2025.